Researchers have developed a non-invasive biomarker, or indicator, using a non-invasive measurement of electrical activity in the brain, to associate a sharp reduction of activity in a specific brain region within 48 hours of beginning pharmaceutical treatment in people who proved susceptible to developing thoughts of suicide.